Modified Oral Rapid Drug Desensitization (ORDD) to Ibrutinib in a Patient with Stage IV Mantle Cell Lymphoma and Early Onset Grade 1 Hypersensitivity Reaction

Modified Oral Rapid Drug Desensitization (ORDD) to Ibrutinib in a Patient with Stage IV Mantle Cell Lymphoma and Early Onset Grade 1 Hypersensitivity Reaction

Results The patient tolerated the ORDD to ibrutinib and continues to do well on the medication for treatment of Stage IV mantle cell lymphoma.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2017-02, Vol.139 (2), p.AB38-AB38
Hauptverfasser: Perez, Elena E., MD, PhD, FAAAAI, Stein, Mark R., MD, FAAAAI, Koterba, Alan, MD, PhD, Moskowitz, Bruce, MD, Rothschild, Neal E., MD
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Drug dosages
Lymphoma
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Results The patient tolerated the ORDD to ibrutinib and continues to do well on the medication for treatment of Stage IV mantle cell lymphoma.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2016.12.180